Abstract: Tumor budding has been associated with poor prognosis in several cancer types, but its significance in gastric cancer is unknown. The aim of this study was to assess the prognostic significance of tumor budding in gastric adenocarcinoma, and its main histologic types. Some 583 gastric adenocarcinoma patients who underwent surgery in Oulu University Hospital during the years 1983-2016 were included in this retrospective cohort study. Tumor budding was counted per 0.785 mm 2 fields from the slides originally used for diagnostic purposes. Patients were divided into low-budding (< 10 buds) and high-budding ( ≥ 10 buds) groups. Tumor budding was analyzed in relation to 5-year survival and overall survival. Cox regression was used to calculate hazard ratios (HR) with 95% confidence intervals (CI), adjusted for confounders. Determining tumor budding was difficult in diffuse-type cancer due to the uncohesive growth pattern of these tumors. Patients with high tumor budding had worse 5-year survival compared with patients with low tumor budding (adjusted HR, 1.55; 95% CI, 1.20-2.01). In intestinal-type adenocarcinomas, the high-budding group had significantly poorer 5-year survival compared with the low-budding group (adjusted HR, 1.57; 95% CI, 1.14-2.15). There were no differences in 5-year survival between the budding groups in the diffuse type adenocarcinoma. In conclusion, high tumor budding is an independent prognostic factor in gastric adenocarcinoma, but its value is limited to the intestinal type of gastric adenocarcinoma. In diffuse type gastric adenocarcinoma, the assessment of tumor budding is hardly feasible, and it does not have prognostic relevance.
G astric cancer is the third deadliest cancer in the world, 1 with high rates of recurrence even after potentially curative surgery. 2 TNM classification based on infiltration depth of tumor, number of lymph node metastases, and the presence or absence of distant metastases is the most commonly used method to estimate the prognosis of gastric cancer patients. However, many early-stage gastric cancer patients still die due to cancer. 3 Assessment of histologic patterns might be useful to increase the prognostic accuracy of TNM classification and to help identify high-risk patients who benefit from intensive therapy.
Tumor budding is a novel prognostic factor that has been under interest especially in colorectal cancer. 4 It is defined as the presence of single cells or clusters of 2 to 4 cells, called tumor buds, in the invasive front of the tumor. 4 High tumor budding is a well-established marker of poor prognosis in colorectal cancer, 4 but it has been linked with poor prognosis with various other cancer types, like breast cancer, 5 head and neck squamous cell carcinoma, 6 and pancreatic adenocarcinoma. 7 The prognostic value of tumor budding in gastric cancer is poorly known. Two of the 4 earlier small studies have suggested that budding may be associate with poor prognosis in gastric cancer, [8] [9] [10] [11] but none of the 4 studies counted buds from a single field of vision on hematoxylineosin (HE)-stained slides, which is now recommended in colorectal cancer. 4 The aim of this study was to evaluate the reproducibility of the assessment of tumor budding with the contemporary methods and to clarify the prognostic value of tumor budding in gastric adenocarcinoma and its histologic subsets in a large cohort.
MATERIALS AND METHODS

Study Design
This study was a retrospective cohort study in a single institution in a tertiary care hospital in Northern Finland. There were 601 patients who underwent gastrectomy for gastric cancer in Oulu University Hospital between the years 1983 and 2016. Of these, 583 gastric adenocarcinoma patients had diagnostic glass slides available for analysis and were included in the study. The study was approved by the Oulu University Hospital Ethics Committee. The need to obtain a written or oral consent from the patients was waived by the Finnish National Authority for Medicolegal Affairs (VALVIRA).
Data Collection
The patients were identified from the archives of the Department of Pathology at the Oulu University Hospital, Finland. Clinical data for each patient were obtained from patient records, including operation charts and pathology reports. The immutable national personal numbers assigned to each resident in the country were used to combine data from the patient records and the 100% complete follow-up data from the Causes of Death Registry at the Statistics Finland, available until the end of 2016.
The original, prospectively collected HE diagnostic glass slides used for clinical decision-making were retrieved from the pathology archive and reviewed. Multiple HE-stained sections from each patient were viewed with a light microscope, and a representative section with the deepest invasion was used for further analysis.
Exposure (Tumor Budding)
Sections were scanned and digitized using Aperio AT2 (Leica Biosystems, Wetzlar, Germany), and tumor budding was analyzed from scanned slides using Aperio ImageScope by 2 independent researchers (N.K. and M.E.) blinded to the clinical and outcome data.
Tumor budding was analyzed from the invasive parts of the tumor using the hotspot method, which is considered to be the most useful method for assessing tumor budding in colorectal cancer. 4 A bud was defined as a single tumor cell or a cluster of 2 to 4 tumor cells at the invasive edge of the tumor that appeared to be detached from the main tumor. First, the invasive front of the tumor was screened with low magnification to find the area with most tumor budding. If it was unclear which area had the most tumor budding and if the first area that was screened had under 15 buds, tumor budding was assessed from several areas and the area with the most budding was used for analysis. The number of buds was counted from a single field of view of 0.398 mm 2 using ×200 total magnification, and the number of buds was multiplied by 1.97 to achieve the number of buds per area of 0.785 mm, 2 as recommended for colorectal cancer. 4 The resulting number of buds per 0.785 mm 2 high-power field (HPF) is used for all analyses.
The median number of tumor buds per standardized HPF was 14, and therefore it was decided to divide budding into low (< 10 buds per standardized HPF) and high ( ≥ 10 buds per standardized HPF) budding groups, combining the 2 lowest categories of tumor budding in colorectal cancer (0 to 4 buds and 5 to 9 buds per HPF) into the low budding group in the present study. Examples of low and high tumor budding are shown in Figure 1 . Patients who would have been placed into different subgroups by the 2 investigators had their slides reanalyzed in consultation with an expert gastrointestinal pathologist (T.J.K.), and a consensus was reached.
Outcomes
The primary outcome of the study was 5-year survival, defined as death for any cause during the time between the date of surgery and death of the patient during 5 years or at the end of 5-year follow up.
The secondary outcome of the study was overall survival, defined as death for any cause during the time between the date of surgery and death of the patient or the end of follow up.
Statistical Analysis
All statistical analyses were decided a priori. Cohen kappa was calculated to analyze the interobserver agreement. χ 2 test was used to obtain P-values when comparing categorical variables. Continuous variables were compared, and P-values were obtained by T test. Kaplan-Meier method was used to compare survival between groups, and log-rank test was used to determine statistical significance of differences between groups. Cox regression model was used to perform multivariable analysis, providing hazard ratios (HR) with 95% confidence intervals (CI). Cox regression was adjusted for potential confounding variables: (1) 
RESULTS
Patients
After the retrieval of diagnostic glass slides, a total of 583 surgically treated patients diagnosed with gastric carcinoma were included in the study. The median age of the patients was 69 years (range: 27 to 90 y, interquartile range: 15.4), with 352 (60.4%) of the patients being men and 231 (39.6%) being women. Only 22 (3.8%) of the patients underwent perioperative chemo(radio)therapy. Of these 583 patients, 437 (75.0%) underwent microscopically confirmed R 0 resection, and 146 (25.0%) had R 1/2 resection. The patients with R 1/2 resection included patients with noncurative intent, as well as 34 (5.8%) patients who had distant metastases at the time of surgery. Median follow-up time, including the patients who died during follow-up, was 26 months (range: 0 to 396 mo).
Assessment of Tumor Budding
Tumor budding was analyzed successfully for each patient. Defining tumor budding for the diffuse and mixed subtype tumors turned out to be difficult, as according to the most recent definition by WHO, diffuse subtype cancers include areas with isolated or small groups of tumor cells. 12 Some tumors of diffuse or mixed carcinoma had fewer cell clusters, fulfilling the definition of budding outside the main tumor area. They included, for example, uncohesively growing tumors that had some remaining cell-cell contacts and a low number or absence of detached cells in the invasive front, and intramucosal signet ring cell carcinomas (Fig. 1C) .
The patients were divided into low-budding (< 10 buds) and high-budding ( ≥ 10 buds) groups. In all, 86 slides (14.8% of cases) needed reassessment to reach consensus because they had been placed in different groups by different researchers. The main reasons for reassessments were difficulties in recognizing the area with most buds and distinguishing tumor buds from stroma or immune cells in certain cases. Cohen kappa vas calculated to analyze interobserver agreement after dividing patients into low, moderate, and high-budding groups. Kappa value calculated before the reassessment was 0.706.
After the assessment, 262 (44.9%) of the patients had low tumor budding and 321 (55.1%) had high tumor budding. The patients in the high-budding group were more often operated before the year 2000, were younger, and of the female sex, and had more often advanced TNM stage, diffuse-type histology, high histologic grade, and unradical resection (Table 1) .
Primary Outcome: 5-Year Survival
The primary outcome occurred in 387 (66.4%) of the 583 patients. The 5-year survival was significantly higher in the low-budding group (41.0%) compared with the highbudding group (23.0%, log-rank test P < 0.001, Fig. 2 ). In the univariable analysis, the high-budding group had significantly worse survival compared with the low-budding group (HR, 1.67; 95% CI, 1.36-2.05, Table 2 ). In multivariable analysis, the high-budding group had significantly worse survival compared with the low-budding group (adjusted HR, 1.55; 95% CI, 1.20-2.01, Table 2 ).
In the subgroup analysis of the patients with intestinal histologic type, the 5-year survival was 37.4% in the lowbudding group and 13.2% in the high-budding group (Fig. 2) . The difference between groups was statistically significant (log-rank test P < 0.001). In the univariable analysis, the highbudding group had significantly worse survival compared with the low-budding group (HR, 1.92; 95% CI, 1.43-2.57, Table 2 ).
In the multivariable analysis, the high-budding group had significantly poorer 5-year survival compared with the lowbudding group (adjusted HR, 1.57; 95% CI, 1.14-2.15, Table 2) In the diffuse type histology subgroup, the 5-year survival was 53.1% in the low-budding group and 26.4% in the high-budding group. In the univariable analysis, the difference between the low and high-budding groups was statistically significant (HR, 2.00; 95% CI, 1.27-3.16). However, adjustment for confounders mitigated this difference in 5-year survival for diffuse-type adenocarcinoma (Table 2 ).
Secondary Outcome: Overall Survival
In univariable analysis, patients with high tumor budding had significantly worse survival (HR, 1.46; 95% CI, 1.22-1.75, Table 2 ) compared with those with low tumor budding. In multivariable analysis, patients with high tumor budding had significantly worse survival (adjusted HR, 1.40; 95% CI, 1.12-1.76, Table 2 ) compared with those with low budding.
In the subgroup analysis of intestinal histologic type, patients in the high tumor budding group had significantly worse survival (adjusted HR, 1.39; 95% CI, 1.03-1.87, Table 2 ) compared with the low tumor budding group.
In the diffuse type histology subgroup, the patients with high tumor budding had borderline worse survival compared with those with low budding in the multivariable analysis (adjusted HR, 1.54; 95% CI, 1.01-2.34, Table 2 ).
DISCUSSION
The results of the present study suggest that tumor budding is a reproducible and independent prognostic factor in intestinal-type gastric cancer. In diffuse-type gastric cancer, the assessment of tumor budding might not be feasible and does not seem to have prognostic relevance.
Strengths and limitations of the present study should be considered before interpreting the results. This study was a retrospective single-institution study, which can limit its applicability to larger populations. Nevertheless, this study is much larger than any of the previous studies on the topic. [8] [9] [10] [11] The long study period , during which the treatment of gastric cancer has evolved, and other potential confounding, might be considered as limitations. However, these limitations were counteracted by adjusting multivariate analysis for year of surgery and all other confounders. Patients with unradical resections were also included to minimize selection bias and maximize the power of this study, and multivariate analyses were adjusted for radicality of resection instead. Another strength of the present study is its contemporary hotspot method of assessing tumor budding. The 4 earlier studies on tumor budding in gastric cancer used the method of screening several fields of vision and counting the average amount of buds per field of vision. [8] [9] [10] [11] However, this average budding method is no longer recommended in colorectal cancer, and hotspot method, in which a single standardized 0.785 mm 2 field of vision with the highest amount of tumor budding is assessed. 4 Multiplying the number of buds counted from a smaller field of vision to estimate the buds per standardized HPF might reduce the accuracy of the assessment to some extent, compared with actually counting tumor buds on this area, but the difference is likely small. Furthermore, using the established 0.785 mm 2 area of assessment is justifiable based on the evidence in colorectal cancer wherein this has been suggested as more replicable and comparable. 4 Four previous small studies on tumor budding and prognosis in gastric cancer have been conducted. A Turkish study including 126 patients with T1 gastric cancer reported that tumor budding-positive patients had more lymph node metastases compared with the lymph node-negative group (odds ratio, 8.87; 95% CI, 2.79-22.16). 11 A Danish study (n = 52) including only patients with intestinal histology reported a HR of 1.60 for recurrence in the high-budding group (defined as average number of buds in 10 fields being ≥ 1) compared with the low-budding (< 1 bud in 10 fields on average) group in multivariate analysis, but the result was not statistically significant (P = 0.08). 10 A Japanese study (n = 153) using cytokeratin-stained slides for analysis suggested that high budding ( > 10 buds in a single-field hotspot with ×40 objective) is associated with poor prognosis (HR, 1.61; 95% CI, 1.12-2.41 in univariate analysis), but tumor budding was not an independent prognostic factor based on multivariate analysis in their study. 8 A Chinese study (n = 296) also suggested that high tumor budding, defined as ≥ 5 buds in 10 HPF on average, is associated with poor survival (HR, 1.57; 95% CI, 1.04-2.35 in multivariate analysis). 9 In the present study, the HR for 5-year mortality in the high-budding group was 1.55 (95% CI, 1.20-2.01) in the high-budding group compared with the low-budding group in multivariate analysis, which is similar to the 2 previous studies comparing survival between low-budding and high-budding groups. 8, 9 Taken together, the studies suggest that tumor budding is an independent prognostic factor in gastric cancer.
Tumor budding in different histologic types of gastric cancer has not previously been analyzed in depth in previous studies. [8] [9] [10] [11] In 2 studies, the diffuse type cancers were excluded because of the difficulties in defining tumor budding in those cases. 8, 10 The Chinese study of 296 patients included all histologic subtypes but did not provide subgroup analysis. 9 The Turkish study focusing on only early gastric cancer also included both histologic types but did not provide subgroup analysis. 11 In the present study, high tumor budding was a strong 5-year and overall prognostic factor in the intestinal-type subgroup, while its value was limited in the diffuse-type subgroup and not significant for 5-year survival after adjustment. Because low budding was observed often in intramucosal diffuse tumors, other factors than tumor budding, such as tumor stage and unradical surgery, are more likely to explain the association between high budding and poor prognosis in diffuse-type cancers. As there are also clear problems with defining tumor budding in the diffuse histologic type, tumor budding should probably be used as a prognostic factor only in the intestinal-type gastric cancer.
Tumor buds have been shown to arise from parts of tumor-expressing markers that are associated with epithelialto-mesenchymal transition (EMT). 13 EMT has been shown to increase invasive and metastatic capabilities of cancer cells, 14 which might explain why patients with high tumor budding have worse outcomes than those who with low tumor budding. Several potential treatments that target EMT in different cancer types are being developed, 15 and could benefit gastric cancer patients with high tumor budding.
There are some clinical and research implications for the present study. Tumor budding can be routinely analyzed with HE-stained slides, making it easy and cost-efficient to adopt for clinical use, to estimate prognosis and the need for adjuvant therapies in those with intestinal-type gastric cancer. However, large retrospective and/or prospective studies are needed, first, to establish and validate an optimal cutoff for tumor budding in intestinal-type gastric cancer and to assess the value of tumor budding in clinical decision-making. Further studies or clinical use of tumor budding in diffuse-type gastric cancer are not recommended.
In conclusion, high tumor budding is an independent prognostic factor in gastric adenocarcinoma, more specifically in intestinal-type gastric adenocarcinoma. Assessment of tumor budding in diffuse-type gastric adenocarcinoma is not recommended.
